This trial recruited 20 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% or greater who failed prior frontline platinum-based therapy were randomized to receive pembrolizumab with SNK01 (N=14) or pembrolizumab monotherapy(n=6)….The median PFS was 6.2 vs 1.7 months (Pembrolizumab + NK cells vs Pembrolizumab monotherapy), with significantly higher PFS by log-rank test [HR 0.15 95% CI: 0.05ᅳ0.53, p-value: 0.003]....this study shows that NK cells with pembrolizumab could be better than pembrolizumab alone for NSCLC.